Blue test tubes arranged in a line, disappearing into the background

Drug news

EU approves Xultophy for treatment of Type 2 Diabetes- Novo Nordisk

Read time: 1 mins

Last updated:18th Sep 2014

Published:18th Sep 2014

Source: Pharmawand

Novo Nordisk announced that the European Commission has granted marketing authorisation for Xultophy for the treatment of Type 2 Diabetes Mellitus in adults. The authorisation covers all 27 European Union member states. Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).

Xultophy is indicated for the treatment of adults with Type 2 Diabetes Mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Complete Response from FDA for dasiglucagon to prevent and treat congenital hypoglycemia

Zealand Pharma A/S announced that the FDA has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing

1 mins

Drug news

Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) as perioperative treatment regimen in patients with resected, locally advanced head and neck squamous cell carcinoma

The study evaluated Keytruda as neoadjuvant therapy, then continued after surgery in combination with standard-of-care radiotherapy (with or without cisplatin) as adjuvant therapy, followed by Keytruda as maintenance therapy, compared to adjuvant radiotherapy (with or without cisplatin) alone

2 min

Drug news

Positive data for Arexvy, respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons

GSK plc announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older, including those at increased risk over three full RSV seasons (NCT04886596)

1 min

See all news